Fundraising FoxForbion — 2020 Investments
6 investments dated 2020 · listed companies and verified rows first · show all
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOxana Beskrovnaya, Ph.D.(Executive Officer)John G. Cox(President and Chief Executive Officer)in
Board seatDirk Kersten· per SEC Form D
Co-investorsAtlas VentureMPM BioImpactVida VenturesWellington ManagementHercules Capital, Inc.RA Capital
Azafaros is a clinical-stage biopharmaceutical company developing small-molecule therapies for severe rare genetic metabolic disorders, including GM1/GM2 gangliosidoses, Niemann-Pick type C disease, and other conditions.
BiotechDeep TechHealthtechMedical DevicesLeiden, NL
Hans Aerts(Professor)Hermen Overkleeft(Professor)Stan van Boeckel(Professor)
Co-investorsBioGeneration VenturesBioMedPartnersJeito CapitalPictet GroupAsahi Kasei Corporate Venture CapitalSeroba Life Sciences
CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.
BiotechDeep TechHealthtechMunich, DE
Jörg Wischhusen(Scientific Co-founder)Scott Clarke(Chief Executive Officer)inPeter Garcia(Chief Financial Officer)Sujata Rao(Chief Medical Officer)inStefan Ries(Chief Scientific Officer and Head of Munich Site)inAndrea Goddard(Chief Technical Officer)in
Co-investorsBrandon CapitalJeito CapitalBioqube VenturesBayern KapitalBioGeneration VenturesCanaan Partners+3 more
SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases.
BiotechHealthtechMedical Devices
Ray Barlow(Chief Executive Officer)in
Co-investorsHealthCapBioqube VenturesGimvMedicxiRed Tree Venture
NorthSea Therapeutics is a clinical-stage biopharmaceutical company developing oral fatty acid-derived therapies for liver and metabolic diseases, including intestinal failure-associated liver disease (IFALD), severe hypertriglyceridemia, and MASH.
BiotechDigital HealthHealthtech
Co-investorsNew Science VenturesvenBio PartnersYsios CapitalBGVNovo HoldingsBioGeneration Ventures+1 more
Prilenia is a biotechnology company developing treatments for neurodegenerative diseases, including Huntington's disease and amyotrophic lateral sclerosis (ALS).
BiotechHealthtechMedical Devices
Co-investorsALS Investment FundSV Health InvestorsAmplitude Venture Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.